Bern Center for Precision Medicine Founded

28 Feb 2019
Holly McHugh
Administrator / Office Personnel

Industry news

Precision medicine “tailored” to individual patients is regarded as the medicine of the future. It is already being practiced at the University of Bern and Inselspital, Bern University Hospital. The new Bern Center for Precision Medicine will exploit synergies and strengthen the medicinal location in Bern.

With the support of the Canton of Bern, the University of Bern and the Insel Gruppe have founded the Bern Center for Precision Medicine (BCPM). The BCPM started its operations in January. It will be officially opened on May 20 in the presence of the Director of Education, Ms. Christine Häsler.

“Precision medicine ensures that the right therapy gets to the right patient at the right time,” says Mark A. Rubin, director of the Department for Biomedical Research and head of the newly founded Bern Center for Precision Medicine. “It represents the medicine of the future”. Professor Rubin has international experience in the field of Precision Medicine. He was the founding Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine and the co-Leader of the U.S. National Precision Medicine Program for New York City before being recruited to the University of Bern. Precision medicine incorporates individual characteristics in the treatment, such as genetic predisposition, environmental factors or lifestyle of patients. For instance, existing therapies can be “tailored” in order to avoid adverse effects and to save costs with respect to expensive treatments. Precision Medicine also enables the development of new therapies in which, for example, the body’s own immune system is mobilized in the fight against cancer. Previous therapies are stretched to the limits here, because they assume that human physiology functions similarly or the same way with all humans. But with complex diseases such as cancer, patients respond very differently to therapeutic attempts. Precision medicine takes this into consideration.

Exploit synergies “With the Bern Center for Precision Medicine, we combine the strengths of the university and Inselspital, with their diverse research groups, infrastructures and clinics,” says Christian Leumann, rector of the University of Bern. For Daniel Candinas, vice-rector for research at the University of Bern, this is a logical step: “Precision medicine is a team effort. Doctors and researchers combine their expertise with that of data analysts, and therefore empower clinicians with the best diagnosis and treatment options.” Moreover, the scientific knowledge from the clinics and research groups will flow directly into teaching, says Leumann: “With a new medical curriculum we will be training the first generation of doctors in the field of precision medicine.”

Large data volume as basis for research The Bern Center for Precision Medicine is able to use a large data treasure for research. “As the leading hospital group in Switzerland, we treat innumerable diseases in various stages, and thus have a solid collection of data, which can inform our clinical decisions,” says Matthias Gugger, Director of Teaching and Research, Insel Gruppe. In the meantime, the Insel Gruppe attaches great importance to the protection of personal data: with the Insel Data Science Center it has a new infrastructure which meets the requirements for both data protection and security. Thanks to gene sequencing and bioinformatics, more and more scientific data is being collected, and this data can be analyzed and used for better treatment: “We want to make every patient’s plan of care as unique as their genes,” says Gugger.

Organization as coordination platform Because of its strong role in networking, the BCPM is not configured as a physical center, but as a coordination platform – like the Oeschger Center for Climate Change Research, which has proven to be successful in this form. “With such a structure, a maximum of impact can be achieved with a minimum of effort,” says Rector Leumann. The BCPM is aligned on an interdisciplinary and cross-faculty basis and subordinated to the Executive Board of the University. It combines technical platforms such as the Inselspital’s “Liquid Biobank” or the University of Bern’s “Next Generation Sequencing” platform with organizational units such as the Department of Biomedical Research. Different fields such as genomics, health economics, data protection and statistics are brought together. Specific projects will develop new therapies and methods, also in cooperation with external partners from the realm of science and private enterprise.

Investments are leveraged “Precision medicine has a huge economic potential,” says Mark A. Rubin, head of the Bern Center for Precision Medicine. “Investments in the field are being made internationally”. The Canton of Bern, the University and the Inselspital of Bern have also invested, among other things in gene sequencing, in biobanks for the storage of biological samples, in hard- and software for learning from large amounts of data. "Now it's about using these technologies for diagnostics and research. This requires new and cost-efficient methods and procedures," says Rubin. The Bern Center for Precision Medicine is taking on this task in cooperation with other institutions, such as the Tumor Center of the Inselspital. “All of these initiatives will lead the medicinal location Bern into the future,” says Daniel Candinas, Vice-Rector for Research at the University of Bern. “And the economy will also benefit from a strong healthcare location and from precision medicine”.

Receive more news like this straight to your inbox, become a member for free today>>

Links

Tags

Next Generation SequencingNext-generation sequencing (NGS), also known as whole-genome sequencing, high-throughput sequencing and massive parallel sequencing, produces and analyses thousands to millions of nucleotide sequences at once. Sequencing systems operate via varying technologies depending on the manufacturer, including sequencing by synthesis, ligation, pyrosequencing, ion semiconductor and single-molecule real-time sequencing. For NGS, library preparation is paramount to successful sequencing. In this section, explore a range of library preparation kits, from targeted, amplicon-based or hybridization-based kits including epigenomic, transcriptomic and genomic workflows to fragmentation kits. Find the best next-generation sequencing products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Drug DiscoveryDrug discovery is the process of identifying potential new medications, involving stages such as target identification, compound screening, and preclinical development. It relies on cutting-edge technologies like high-throughput screening, artificial intelligence, and molecular modeling to accelerate the identification of drug candidates. Drug discovery plays a pivotal role in developing new therapies for diseases ranging from cancer to rare genetic disorders. Browse our peer-reviewed product directory to find the latest drug discovery technologies, compare options, check customer feedback, and get pricing directly from manufacturers.Drug DevelopmentDrug development refers to the process of bringing a new drug to market.Precision MedicinePrecision medicine refers to the idea of customized healthcare, where medical decisions and treatments are tailored to the individual patient. Molecular diagnostics, companion diagnostics and Next Generation Sequencing (NGS) play a pivotal role in this approach. Cancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.